Neurology · Major Depressive DisorderTrial Updateclinicalmid-term

Medtronic's Percept PC DBS Study for Treatment Resistant Depression Initiated

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/27/2026, 6:03:02 AM

Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The initiation of Medtronic's study on the Percept PC device for treatment resistant depression (TRD) is significant as it could establish the company as a leader in a niche but critical area of mental health treatment. Success in this trial may not only enhance Medtronic's product offerings but also address a substantial unmet medical need in the TRD segment. Regulatory context from FDA (FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness) supports the near-term read. Assessment grounded in 19 ranked evidence items (8 high-relevance).

Strategic Assessment

Success in this trial may enhance Medtronic's product portfolio and open new market opportunities in neurostimulation for mental health. The strongest clinical anchor is Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV (ClinicalTrials.gov), entity match (major depressive disorder). In Neurology · Major Depressive Disorder, 6 regulatory and 2 competitive items passed relevance filtering for Medtronic.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Efficacy of COPE-A for PTSD and SUD in Young People Demonstrated in RCT. This study could position Medtronic as a leader in innovative treatments for major depressive disorder, particularly in the TRD segment, which is currently underserved.

Regulatory Outlook

Regulatory risk is concentrated around FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. The outcomes of this trial may influence future regulatory approvals and guidelines for the use of DBS in treating major depressive disorder, impacting how the device is marketed and utilized.

Key Risks

Elevated medium regulatory exposure for Medtronic could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, this study could lead to increased market share for Medtronic in the neurostimulation space, potentially translating into significant revenue growth given the large population of treatment-resistant patients.
Upside for Medtronic may improve if Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Medtronic may improve if Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study. (PubMed) delivers favorable follow-through.
Success in this trial may enhance Medtronic's product portfolio and open new market opportunities in neurostimulation for mental health.

What Would Change This Assessment

This becomes more urgent if Monitor recruitment progress, LFP data findings, and results from the discontinuation experiment after 6 months.
Timeline shift beyond mid term would change urgency.
Outcome from FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves First At-home Starting Dose for Alzheimer’s Disease Treatment
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Decision: Doxecitine and Doxribtimine in the treatment of thymidine kinase 2 deficiency (TK2d)
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves New Treatment to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Coronavirus (COVID-19) Update: FDA Warns of Newly Discovered Potential Drug Interaction That May Reduce Effectiveness of COVID-19 Treatment Authorized for Emergency Use
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
ClinicalTrials.govhigh relevance
Entity match (major depressive disorder)
FDA document
View source
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Characterization and Treatment of Adolescent Depression
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Efficacy of COPE-A for PTSD and SUD in Young People Demonstrated in RCT
Humanexa Signalsmedium relevance
Moderate corpus alignment

Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety of crisaborole ointment combined with 308-nm excimer laser in the treatment of non-segmental vitiligo: a randomized, intra-patient left-right controlled study protocol.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Medtronic
Major Depressive Disorder
Treatment Resistant Depression

Commercial impact

medium

If successful, this study could lead to increased market share for Medtronic in the neurostimulation space, potentially translating into significant revenue growth given the large population of treatment-resistant patients.

Regulatory impact

medium

The outcomes of this trial may influence future regulatory approvals and guidelines for the use of DBS in treating major depressive disorder, impacting how the device is marketed and utilized.

What to watch

Monitor recruitment progress, LFP data findings, and results from the discontinuation experiment after 6 months.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.